118 related articles for article (PubMed ID: 34941995)
21. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
22. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
23. Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"by Bonelli
Benucci M; Damiani A; Infantino M; Manfredi M; Grossi V; Lari B; Li Gobbi F; Sarzi Puttini P
Ann Rheum Dis; 2021 Oct; 80(10):e166. PubMed ID: 34340979
[No Abstract] [Full Text] [Related]
24. Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2.
Krsak M; Harry BL; Palmer BE; Franco-Paredes C
Viral Immunol; 2021 Oct; 34(8):504-509. PubMed ID: 34227891
[TBL] [Abstract][Full Text] [Related]
25. The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients.
Duni A; Markopoulos GS; Mallioras I; Pappas H; Pappas E; Koutlas V; Tzalavra E; Baxevanos G; Priska S; Gartzonika K; Mitsis M; Dounousi E
Front Immunol; 2021; 12():760249. PubMed ID: 34925330
[TBL] [Abstract][Full Text] [Related]
26. Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination.
Brumfiel CM; Patel MH; DiCaudo DJ; Rosenthal AC; Pittelkow MR; Mangold AR
Leuk Lymphoma; 2021 Oct; 62(10):2554-2555. PubMed ID: 33974494
[No Abstract] [Full Text] [Related]
27. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
28. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
[TBL] [Abstract][Full Text] [Related]
29. [Vaccination immunology in SARS-CoV-2].
Helweg-Larsen J; Benfield T
Ugeskr Laeger; 2021 Mar; 183(11):. PubMed ID: 33734074
[TBL] [Abstract][Full Text] [Related]
30. T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?: Commentary for: "Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.".
Bsteh G; Sellner J
EBioMedicine; 2021 Dec; 74():103692. PubMed ID: 34773893
[No Abstract] [Full Text] [Related]
31. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
32. Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients.
Oh BLZ; Tan N; de Alwis R; Kunasegaran K; Chen Z; Poon M; Chan E; Low JGH; Yeoh AEJ; Bertoletti A; Le Bert N
Blood; 2022 Jul; 140(2):156-160. PubMed ID: 35472242
[TBL] [Abstract][Full Text] [Related]
33. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
Gardner R; Wu D; Cherian S; Fang M; Hanafi LA; Finney O; Smithers H; Jensen MC; Riddell SR; Maloney DG; Turtle CJ
Blood; 2016 May; 127(20):2406-10. PubMed ID: 26907630
[TBL] [Abstract][Full Text] [Related]
34. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
35. Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
Fox TA; Kirkwood AA; Enfield L; O'Reilly M; Arulogun S; D'Sa S; O'Nions J; Kavi J; Vitsaras E; Townsend W; Burns SO; Gohil SH; Cwynarski K; Thomson KJ; Noursadeghi M; Heyderman RS; Rampling T; Ardeshna KM; McCoy LE; Morris EC
Br J Haematol; 2021 Dec; 195(5):706-709. PubMed ID: 34545952
[No Abstract] [Full Text] [Related]
36. [Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells].
Xiao X; Yuan T; Meng JX; Jiang YY; Cao YQ; Li Q; Sun R; Zhao MF
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(8):593-598. PubMed ID: 32164113
[No Abstract] [Full Text] [Related]
37. Point mutation in
Zhang Z; Chen X; Tian Y; Li F; Zhao X; Liu J; Yao C; Zhang Y
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33023981
[TBL] [Abstract][Full Text] [Related]
38. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
[No Abstract] [Full Text] [Related]
39. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
[TBL] [Abstract][Full Text] [Related]
40. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
Del Fresno C; García-Arriaza J; Martínez-Cano S; Heras-Murillo I; Jarit-Cabanillas A; Amores-Iniesta J; Brandi P; Dunphy G; Suay-Corredera C; Pricolo MR; Vicente N; López-Perrote A; Cabezudo S; González-Corpas A; Llorca O; Alegre-Cebollada J; Garaigorta U; Gastaminza P; Esteban M; Sancho D
Front Immunol; 2021; 12():748103. PubMed ID: 34867974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
